Download Files:

Sacubitril-d4

$430

Only 1000 item(s) left in stock.

Products Details

Product Description

– Sacubitril-d4 is the deuterium labeled Sacubitril. Sacubitril (AHU-377) is a potent NEP inhibitor with an IC50 of 5 nM. Sacubitril (AHU-377) is a component of the heart failure medicine LCZ696.

Web ID

– HY-15407S

Shipping

– Room temperature

Applications

– Neuroscience-Neuromodulation

Molecular Formula

– C24H25D4NO5

References

– [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.|[2]Ksander GM, et al. Dicarboxylic acid dipeptide neutral endopeptidase inhibitors. J Med Chem. 1995 May 12;38(10):1689-700.|[3]Voors AA, et al. The potential role of valsartan + AHU377 ( LCZ696 ) in the treatment of heart failure. Expert Opin Investig Drugs. 2013 Aug;22(8):1041-7.|[4]von Lueder TG, et al. Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy. Circ Heart Fail. 2015 Jan;8(1):71-8.

CAS Number

– 1884269-07-1

Molecular Weight

– 415.52

SMILES

– C[C@H](C[C@@H](CC1=CC=C(C=C1)C2=CC=CC=C2)NC(C([2H])(C([2H])(C(O)=O)[2H])[2H])=O)C(OCC)=O

Clinical Information

– No Development Reported

Research Area

– Cardiovascular Disease

Solubility

– 10 mM in DMSO

Target

– Neprilysin

Pathway

– Metabolic Enzyme/Protease

Product type

– Isotope-Labeled Compounds

Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.

My Cart
Close Wishlist
Close Recently Viewed
Categories

Please fill out this form to request the file. We will send it to your Email address shortly. Thanks.

Please enable JavaScript in your browser to complete this form.

Please fill out this form to request the pricing.
We will send it to your email address shortly.
Thanks.

Please enable JavaScript in your browser to complete this form.